Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 3Uterine Cervical Neoplasms 2Rectal Neoplasms 1Radiation Injuries 1Neoplasms 1Lichen Planus, Oral 1Gastrointestinal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Prednisone 9Pemetrexed 9Epoetin Alfa 9venetoclax 8atezolizumab 8Fentanyl 8Drug Therapy 8Doxorubicin 8Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Erythropoietin × Clear all
NCT05704894 2023-01-30

Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens

Blau Farmaceutica S.A.

Phase 3 Unknown
320 enrolled
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡